Document:

Exhibit 10.10

 

FORM OF INSTITUTIONAL
BROKER WARRANT

 

WARRANT

 

NEITHER THE SECURITIES
REPRESENTED HEREBY NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATES. THESE SECURITIES ARE
SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES
ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM, AS EVIDENCED BY A LEGAL OPINION
OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, WHICH OPINION SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

NEUROTROPE, INC.

 

WARRANT

 

	Warrant No. IBW-1-2015	Original Issue Date:
	 	November 13, 2015

 

This Common Stock Purchase
Warrant (the “Broker Warrant”) certifies that, for value received, Katalyst Securities, LLC (the “Holder”),
subject to the terms set forth herein, is entitled to purchase from Neurotrope, Inc., a Nevada corporation (the “Company”)
up to a total of [_______] shares of Common Stock (each such share, a “Broker Warrant Share” and all such shares,
the “Broker Warrant Shares”), at any time and from time to time from and after the Original Issue Date and through
and including November 13, 2020 (the “Expiration Date”), and subject to the following terms and conditions:

 

1.           Definitions.
As used in this Broker Warrant, the following terms shall have the respective definitions
set forth in this Section 1.

 

“Closing Price”
means, for any date of determination, the price determined by the first of the following clauses that applies: (i) if the Common
Stock is then listed or quoted on a Trading Market, the closing sales price per share of the Common Stock for such date (or the
nearest preceding date) on such market; (ii) if prices for the Common Stock are then quoted on the OTC Bulletin Board, the closing
sales price per share of the Common Stock for such date (or the nearest preceding date) so quoted; (iii) if prices for the Common
Stock are then reported in the OTC Markets, the most recent sales price per share of the Common Stock so reported; or (iv) in all
other cases, the fair market value of a share of Common Stock as determined by a good faith determination of the Company’s
board of directors.

 

“Common Stock”
means the common stock of the Company, par value $0.0001 per share, and any securities into which such common stock may hereafter
be reclassified.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

     

     

    

 

“Exercise
Price” means $1.50, subject to adjustment in accordance with Section 9; provided, however, upon the exercise (if any)
of all of the Series A Warrants or all of the Series B Warrants (as such terms are defined in the Securities Purchase Agreement),
“Exercise Price” means $0.80, subject to adjustment in accordance with Section 9.

 

“Fundamental
Transaction” means any of the following: (i) the Company effects any merger or consolidation of the Company with or into
another person, (ii) the Company effects any sale of all or substantially all of its assets in one or a series of related transactions,
(iii) any tender offer or exchange offer (whether by the Company or another person) is completed pursuant to which holders of Common
Stock are permitted to tender or exchange their shares for other securities, cash or property, or (iv) the Company effects any
reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property.

 

“Offering”
means the period which Holder is engaged by the Company to act as non-exclusive placement agent in connection with the private
placement of the units of the Company, as further outlined in the Securities Purchase Agreement.

 

“Original
Issue Date” means the Original Issue Date first set forth on the first page of this Broker Warrant or its predecessor
instrument.

 

“Securities
Purchase Agreement” means that certain Securities Purchase Agreement, dated November 13, 2015, between the Company the
investors listed in the Schedule of Buyers attached thereto.

 

“Registration
Rights Agreement” means the Registration Rights Agreement, dated November 13, 2015, between the Company and each of the
Buyers identified on Exhibit A attached thereto.

 

“Trading Day”
means (i) a day on which the Common Stock is traded on a Trading Market (other than the OTC Bulletin Board), or (ii) if the Common
Stock is not listed on a Trading Market (other than the OTC Bulletin Board), a day on which the Common Stock is traded in the over-the-counter
market, as reported by the OTC Bulletin Board, or (iii) if the Common Stock is not quoted on any Trading Market, a day on which
the Common Stock is quoted in the over-the-counter market as reported by the OTC Markets (or any similar organization or agency
succeeding to its functions of reporting prices); provided, that in the event that the Common Stock is not listed or quoted as
set forth in clauses (i), (ii) and (iii) hereof, then Trading Day shall mean any day, except a Saturday, Sunday or legal holiday,
on which banking institutions in the city of New York are authorized or obligated by law or executive order to close (a “Business
Day”).

 

“Trading Market”
means whichever of the New York Stock Exchange, NYSE MKT, the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ
Capital Market or the OTC Bulletin Board on which the Common Stock is listed or quoted for trading on the date in question.

 

     

     

    

 

2.           Registration
of Warrant. The Company shall register this Broker Warrant
upon records to be maintained by the Company’s transfer agent for that purpose
(the “Warrant Register”), in the name of the record Holder
hereof from time to time. The Company may deem and treat the registered Holder
of this Broker Warrant as the absolute owner hereof for the purpose of any exercise
hereof or any distribution to the Holder, and for all other purposes, absent proper notice
to the contrary in accordance with the provisions of this Broker Warrant.

 

3.           Registration
of Transfers. The Company’s transfer agent shall register the permitted transfer
of any portion of this Broker Warrant in the Warrant Register,
upon receipt of this Broker Warrant and the Form of Assignment attached hereto duly completed
and signed at its address specified herein. Upon any such registration or transfer, a new warrant
to purchase Common Stock, in substantially the form of this Broker
Warrant (any such new warrant, a “New Warrant”),
evidencing the portion of this Broker Warrant so transferred shall be issued to the transferee
and a New Warrant evidencing the remaining portion of this Broker
Warrant not so transferred, if any, shall be issued to the transferring Holder. The
acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by
such transferee of all of the rights and obligations of a holder of a New
Warrant.

 

4.           Exercise
and Duration of Warrants.

 

(a)          This
Broker Warrant shall be exercisable by the registered Holder
in whole at any time and in part from time to time from the Original Issue Date through
and including the Expiration Date. At 5:00 p.m., New York time on the Expiration
Date, the portion of this Broker Warrant not exercised prior thereto shall be and
become void and of no value.

 

(b)          Notwithstanding
anything to the contrary contained herein, the number of Broker Warrant Shares that may
be acquired by the Holder upon any exercise of this Broker
Warrant (or otherwise in respect hereof) shall be limited to the extent necessary to insure that, following such exercise
(or other issuance), the total number of shares of Common Stock then beneficially owned
by such Holder and its affiliates (as defined under Rule 144 promulgated under the Securities
Act, “Affiliates”) and any other persons whose beneficial ownership
of Common Stock would be aggregated with the Holder’s
for purposes of Section 13(d) of the Exchange Act, does not exceed 4.999% of the total number
of issued and outstanding shares of Common Stock (including for such purpose the shares
of Common Stock issuable upon such exercise). For such purposes, beneficial ownership shall
be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. This provision shall not restrict the number of shares of Common
Stock which a Holder may receive or beneficially own in order to determine the amount
of securities or other consideration that such Holder may receive in the event of a Fundamental
Transaction as contemplated in Section 9 of this Broker Warrant. By written notice
to the Company, the Holder may waive the provisions
of this Section 4(b) but any such waiver will not be effective until the 61st day after
delivery of such notice, nor will any such waiver effect any other Holder.

 

     

     

    

 

Notwithstanding anything
to the contrary contained herein, the number of Broker Warrant Shares that may be acquired by the Holder upon any exercise of this
Broker Warrant (or otherwise in respect hereof) shall be limited to the extent necessary to insure that, following such exercise
(or other issuance), the total number of shares of Common Stock then beneficially owned by such Holder and its Affiliates and any
other persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d)
of the Exchange Act, does not exceed 9.999% of the total number of issued and outstanding shares of Common Stock (including for
such purpose the shares of Common Stock issuable upon such exercise). For such purposes, beneficial ownership shall be determined
in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. This provision shall
not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount
of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in
Section 9 of this Broker Warrant. This restriction may not be waived.

 

5.           Delivery
of Broker Warrant Shares.

 

(a)          To
effect exercises hereunder, the Holder shall not be required to physically surrender this
Broker Warrant unless this Broker Warrant is being
exercised for all of the remaining Broker Warrant Shares represented by this Broker
Warrant. Upon delivery of the Exercise Notice (in the form attached hereto) to the
Company (with the attached Broker Warrant Shares
Exercise Log) at its address for notice set forth herein and upon payment of the Exercise Price
multiplied by the number of Broker Warrant Shares that the Holder
intends to purchase hereunder in cash or by cashless exercise pursuant to Section 10(b)
hereof, the Company shall promptly (but in no event later than three Trading
Days after the Date of Exercise (as defined herein)) issue and deliver to the Holder,
a certificate for the Broker Warrant Shares issuable upon such exercise, which, if at the
time the Broker Warrant is exercised there is an effective registration statement to cover
the issuance or resale of the Broker Warrant Shares and if the legend is not required by
applicable law, shall be free of restrictive legends. The Company shall deliver any objection
to any such Exercise Notice form within two (2) Business Days of receipt of such notice.
The Company shall, upon request of the Holder and
subsequent to the date on which a registration statement covering the resale of the Broker Warrant
Shares has been declared effective by the United States Securities and Exchange Commission (the “SEC”),
use its reasonable efforts to deliver Broker Warrant Shares hereunder electronically through
the Depository Trust Corporation or another established clearing corporation performing similar functions, if available, provided,
that, the Company may, but will not be required to change its transfer agent if its current
transfer agent cannot deliver Broker Warrant Shares electronically through the Depository
Trust Corporation. A “Date of Exercise” means the date on which the Company
has received from the Holder: (i) the Exercise
Notice (with the Broker Warrant Exercise Log attached to it), appropriately completed and
duly signed and (ii) if such Holder is not utilizing
the cashless exercise provisions set forth in this Broker Warrant, payment of the Exercise
Price for the number of Broker Warrant Shares so indicated by the Holder
to be purchased.

 

(b)          If
by the third Trading Day after a Date of Exercise the
Company fails to deliver the required number of Broker Warrant Shares in the manner required
pursuant to Section 5(a), then the Holder will have
the right to rescind such exercise.

 

(c)          The
Company’s obligations to issue and deliver Broker
Warrant Shares in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction
by the Holder to enforce the same, any waiver or consent with respect to any provision hereof,
the recovery of any judgment against any person or any action to enforce the same, or any
setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder
or any other person of any obligation to the Company
or any violation or alleged violation of law by the Holder or any other person,
and irrespective of any other circumstance which might otherwise limit such obligation of the Company
to the Holder in connection with the issuance of Broker
Warrant Shares. Nothing herein shall limit a Holder’s right to pursue any other
remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or
injunctive relief with respect to the Company’s failure to timely deliver certificates
representing Broker Warrant Shares upon exercise of this Broker
Warrant as required pursuant to the terms hereof.

 

     

     

    

 

6.           Charges,
Taxes and Expenses. Issuance and delivery of Broker Warrant Shares upon exercise of
this Broker Warrant shall be made without charge to the Holder
for any issue or transfer tax, withholding tax, transfer agent fee or other incidental tax or expense in respect of the
issuance of such certificates to the Holder, all of which taxes and expenses shall be paid
by the Company; provided, however, that the Company shall
not be required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificates
for Broker Warrant Shares or Warrants in a name other than that of the Holder.
The Holder shall be responsible for all other tax liability that may arise as a result of
holding or transferring this Broker Warrant or receiving Broker
Warrant Shares upon exercise hereof.

 

7.           Replacement
of Warrant. If this Broker Warrant is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution
for this Broker Warrant, a New Warrant, but only
upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction
and customary and reasonable indemnity (which shall not include a surety bond), if requested. Applicants for a New
Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other
reasonable third-party costs as the Company may prescribe. If a New
Warrant is requested as a result of a mutilation of this Broker Warrant, then the
Holder shall deliver such mutilated warrant to the Company
as a condition precedent to the Company’s obligation to issue the New
Warrant.

 

8.           Reservation
of Broker Warrant Shares. The Company covenants
that it will at all times reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved
Common Stock, solely for the purpose of enabling it to issue Broker
Warrant Shares upon exercise of this Broker Warrant as herein provided, the number
of Broker Warrant Shares which are then issuable and deliverable upon the exercise of this
entire Broker Warrant, free from preemptive rights or any other contingent purchase rights
of persons other than the Holder (taking into account the adjustments and restrictions of
Section 9). The Company covenants that all Broker
Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise
Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable.

 

9.           Certain
Adjustments. The Exercise Price and number of Broker
Warrant Shares issuable upon exercise of this Broker Warrant are subject to adjustment
from time to time as set forth in this Section 9.

 

     

     

    

 

(a)          Stock
Dividends and Splits. If the Company, at any time while this Broker
Warrant is outstanding, (i) pays a stock dividend on its Common
Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common
Stock, (ii) subdivides outstanding shares of Common
Stock into a larger number of shares, or (iii) combines outstanding shares of Common
Stock into a smaller number of shares, then in each such case the Exercise Price shall
be adjusted to equal the product obtained by multiplying the then-current Exercise Price by
a fraction of which the numerator shall be the number of shares of Common Stock outstanding immediately
before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution, and any adjustment
pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision
or combination.

 

(b)          Fundamental
Transactions. If, at any time while this Broker Warrant is outstanding
there is a Fundamental Transaction, then the Holder
shall have the right thereafter to receive, upon exercise of this Broker Warrant,
the same amount and kind of securities, cash or property as it would have been entitled
to receive upon the occurrence of such Fundamental Transaction if it had been, immediately
prior to such Fundamental Transaction, the holder of
the number of Broker Warrant Shares then issuable upon exercise in full of this Broker
Warrant (the “Alternate Consideration”). For purposes of any such
exercise, the determination of the Exercise Price shall be appropriately adjusted to apply
to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise
Price among the Alternate Consideration in a reasonable manner reflecting the relative
value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall
be given the same choice as to the Alternate Consideration it receives upon any exercise
of this Broker Warrant following such Fundamental Transaction.
At the Holder’s option and request, any successor to the Company
or surviving entity in such Fundamental Transaction shall issue to the Holder
a new warrant substantially in the form of this Broker
Warrant and consistent with the foregoing provisions and evidencing the Holder’s
right to purchase the Alternate Consideration for the aggregate Exercise
Price upon exercise thereof. The terms of any agreement pursuant to which a Fundamental
Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions
of this paragraph (b) and insuring that the Broker Warrant
(or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental
Transaction.

 

(c)          Number
of Broker Warrant Shares. Simultaneously with any adjustment to the Exercise
Price pursuant to this Section 9, the number of Broker
Warrant Shares that may be purchased upon exercise of this Broker Warrant shall be
increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price
payable hereunder for the adjusted number of Broker Warrant Shares shall be the same
as the aggregate Exercise Price in effect immediately prior to such adjustment.

 

(d)          Calculations.
 All calculations under this Section 9 shall be made to the nearest cent or the nearest
1/100th of a share, as applicable. The number of shares of Common Stock outstanding
at any given time shall not include shares owned or held by or for the account of the Company,
and the disposition of any such shares shall be considered an issue or sale of Common Stock.

 

     

     

    

 

(e)          Notice
of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the
Company at its expense will promptly compute such adjustment in accordance with the terms
of this Broker Warrant and prepare a certificate setting forth such adjustment, including
a statement of the adjusted Exercise Price and adjusted number or type of Broker
Warrant Shares or other securities issuable upon exercise of this Broker Warrant (as
applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment
is based. Upon written request, the Company will promptly deliver a copy of each such certificate
to the Holder and to the Company’s transfer
agent.

 

10.         Payment
of Exercise Price.  The Holder may pay the Exercise
Price in one of the following manners:

 

(a)          Cash
Exercise. The Holder may deliver immediately available funds; or

 

(b)          Cashless
Exercise. If an Exercise Notice is delivered at a time when a registration statement permitting the Holder
to resell the Broker Warrant Shares is not then effective or the prospectus forming
a part thereof is not then available to the Holder for the resale of the Broker
Warrant Shares, then the Holder may notify the Company
in an Exercise Notice of its election to utilize a cashless exercise, in which event the Company
shall issue to the Holder the number of Broker Warrant
Shares determined as follows:

 

X = Y [(A-B)/A]

 

where:

 

X = the number
of Broker Warrant Shares to be issued to the Holder.

 

Y = the number
of Broker Warrant Shares with respect to which this Broker Warrant is being exercised.

 

A = the average
of the Closing Prices for the twenty Trading Days immediately prior to (but not including) the Date of Exercise.

 

B = the Exercise
Price.

 

For purposes of Rule
144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Broker Warrant Shares issued in
a cashless exercise transaction shall be deemed to have been acquired by the Holder, and the holding period for the Broker Warrant
Shares shall be deemed to have commenced, on the date this Broker Warrant was originally issued.

 

11.         No
Fractional Shares of Scrip.  No fractional shares or scrip representing fractional shares of Broker
Warrant Shares will be issued in connection with any exercise of this Broker Warrant.
As to any fraction of a share that Holder would otherwise be entitled to purchase upon such
exercise, the Company shall round up, as nearly as practicable to the nearest whole share
of Common Stock, the number of Broker Warrant Shares to
be issued.

 

     

     

    

 

12.         Notices.
Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall
be in writing and shall be deemed effectively given to a party if (a) by personal delivery; (b)
upon deposit with the United States Post Office, by certified mail, return receipt requested, first-class mail, postage prepaid;
(c) delivered by hand or by messenger or overnight courier, addressee signature required, to the addresses below or at such other
address and/or to such other persons as shall have been furnished by the parties:

 

	If to the Company:	Neurotrope, Inc.
	 	50 Park Place, Suite 1401
	 	Newark, NJ 07102
	 	Attn:  Chief Executive Office
	 	 
	With a copy to:	Reed Smith LLP
	(which shall not constitute notice)	136 Main Street, Suite 250
	 	Princeton, NJ 08540
	 	Attn:  Nanette W. Mantell, Esq.
	 	 
	If to Katalyst Securities, LLC.	Katalyst Securities, LLC
	 	15 Maiden Lane, Room 601
	 	New York, NY 10038
	 	Attention:  Paul Ehrenstein
	 	President
	 	 
	With a copy to:	Barbara J. Glenns, Esq.
	(which shall not constitute notice)	Law Office of Barbara J. Glenns, Esq.
	 	30 Waterside Plaza, Suite 25G
	 	New York, NY 10010

 

In case any time: (1)
the Company shall declare any cash dividend on its capital stock; (2) the Company
shall pay any dividend payable in stock upon its capital stock or make any distribution to the holders of its capital stock;
(3) the Company shall offer for subscription pro rata to the holders of its capital stock
any additional shares of stock of any class or other rights; (4) there shall be any capital reorganization, or reclassification
of the capital stock of the Company, or consolidation or merger of the Company
with, or sale of all or substantially all of its assets to, another corporation; or (5) there shall be a voluntary or involuntary
dissolution, liquidation or winding up of the Company; then, in any one or more of said
cases, the Company shall give written notice to the Holder.
Such notice shall also specify the date as of which the holders of capital stock of record shall participate in such dividend,
distribution or subscription rights, or shall be entitled to exchange their capital stock for securities or other property deliverable
upon such reorganization, reclassification, consolidation, merger, sale, dissolution, liquidation or winding up, or conversion
or redemption, as the case may be; provided, however, in each case that such information shall be made known to the public through
a press release, filing with the SEC, or other public announcement prior to or in conjunction
with such notice being provided to the Holder, the failure to mail such notice or any defect
therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice.
Such written notice shall be given at least 10 days prior to the action in question and not less than 10 days prior to the record
date or the date on which the Company’s transfer books are closed in respect thereto.

 

     

     

    

 

13.         Registration
Rights. The Holder shall be entitled to the registration rights set forth in the Registration
Rights Agreement.

 

14.         Lock
Up. In accordance with FINRA Rule 5110(g), this Broker Warrant shall not be sold during
the Offering, or sold, transferred, assigned, pledged, or hypothecated, or be the subject
of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of this
Broker Warrant or the Broker Warrant Shares, by any
person for a period of 180 days immediately following the date of effectiveness or commencement
of sales of the Offering, except as provided in paragraph (g)(2) of FINRA Rule 5110.

 

15.         Transferability.
This Broker Warrant and all rights hereunder are transferable, in whole or in part and with
the Company’s consent (which shall not be unreasonably withheld), upon surrender of
this Broker Warrant at the principal office of the Company,
together with a written assignment of this Broker Warrant substantially in the form attached
hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay
any transfer taxes payable upon the making of such transfer. The Holder represents that
by accepting this Broker Warrant it understands that this Broker
Warrant and any securities obtainable upon exercise of this Broker Warrant may not
be registered for sale under federal or state securities laws and may be being offered and sold to the Holder
pursuant to one or more exemptions from the registration requirements of such securities laws. In the absence of an effective
registration of such securities or an exemption therefrom, any certificates for such securities shall bear the legend set forth
on the first page hereof. The Holder understands that it must bear the economic risk of
its investment in this Broker Warrant and any securities obtainable upon exercise of this
Broker Warrant for an indefinite period of time, as this Broker
Warrant and such securities have not been registered under federal or state securities laws and therefore cannot be sold
unless subsequently registered under such laws, unless an exemption from such registration is available.

 

16.         Miscellaneous.

 

(a)          This
Broker Warrant shall be binding on and inure to the benefit of the parties hereto and their
respective successors and permitted assigns. Subject to the preceding sentence, nothing in this Broker
Warrant shall be construed to give to any person other than the Company
and the Holder any legal or equitable right, remedy or cause of action under this
Broker Warrant. This Broker Warrant may be amended
only in writing signed by the Company and the Holder and
their successors and assigns.

 

(b)          All
questions concerning the construction, validity, enforcement and interpretation of this Broker
Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without
regard to the principles of conflicts of law thereof.

 

(c)          The
headings herein are for convenience only, do not constitute a part of this Broker Warrant and
shall not be deemed to limit or affect any of the provisions hereof.

 

     

     

    

 

(d)          In
case any one or more of the provisions of this Broker Warrant shall be invalid or unenforceable
in any respect, the validity and enforceability of the remaining terms and provisions of this Broker
Warrant shall not in any way be affected or impaired thereby and the parties will attempt in good faith to agree upon a
valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate
such substitute provision in this Broker Warrant.

 

(e)          Prior
to exercise of this Broker Warrant, the Holder hereof
shall not, by reason of by being a Holder, be entitled to any rights of a stockholder with
respect to the Broker Warrant Shares.

 

(f)          The
Holder acknowledges that the Broker Warrant Shares acquired
upon the exercise of this Broker Warrant, if not registered, will contain a legend to that
effect.

 

[Remainder of page
intentionally left blank, signature page follows]

 

     

     

    

 

In witness whereof,
the Company has caused this Broker Warrant to be duly executed by its authorized officer as of the date first indicated above.

 

	 	NEUROTROPE, INC.
	 	 	 
	 	By: 	/s/ Robert Weinstein
	 	 	Name: Robert Weinstein
	 	 	Title:  Chief Financial Officer, Executive
	 	 	Vice President, Secretary and Treasurer

 

     

     

    

 

EXERCISE NOTICE

 

The undersigned Holder
hereby irrevocably elects to purchase __________ shares of Common Stock pursuant to the attached Warrant. Capitalized terms used
herein and not otherwise defined have the respective meanings set forth in the Broker Warrant.

 

(1)         The
undersigned Holder hereby exercises its right to purchase __________ Broker Warrant Shares pursuant to the Broker Warrant.

 

(2)         The
Holder intends that payment of the Exercise Price shall be made as (check one):

 

__________ “Cash
Exercise” under Section 10

 

__________ “Cashless
Exercise” under Section 10

 

(3)         If
the Holder has elected a Cash Exercise, the Holder shall pay the sum of $__________ to the Company in accordance with the terms
of the Broker Warrant.

 

(4)         Pursuant
to this Exercise Notice, the Company shall deliver to the Holder __________ Broker Warrant Shares in accordance with the terms
of the Broker Warrant.

 

	Dated ______________ __, _____	Name of Holder: 
	 	 
	 	(Print)
	 	 
	 	 
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 
	 	 	 
	 	(Signature must conform in all respects to name of holder as specified on the face of the Broker Warrant)

 

     

     

    

 

Broker Warrant Shares
Exercise Log

 

	Date	 	Number of Warrant

Shares Available

to be Exercised	 	Number of Warrant

Shares Exercised	 	Number of Warrant

Shares Remaining

to be Exercised
	 	 	 	 	 	 	 

 

     

     

    

 

FORM OF ASSIGNMENT

 

[To be completed and signed
only upon transfer of Warrant]

 

FOR VALUE RECEIVED,
the undersigned hereby sells, assigns and transfers unto __________ the right represented by the attached Warrant to purchase __________
shares of Common Stock to which such Warrant relates and appoints __________ attorney to transfer said right on the books of the
Company with full power of substitution in the premises.

 

	Dated: __________ __, _______	 
	 	 
	 	 
	 	(Signature must conform in all respects to name of holder as specified on the face of the Broker Warrant)
	 	 
	 	Address of Transferee
	 	 
	 	 
	 	 
	 	 
	 	 
	Attest:Exhibit 10.11

 

NEUROTROPE, INC.

 

AMENDMENT NO. 2 TO

PREFERRED STOCKHOLDERS AGREEMENT

 

This Amendment No.
2 (this “Amendment”) to Preferred Stockholders Agreement (as defined below) is made as of November 13, 2015
(the “Amendment Effective Date”), by and among the stockholders who are a party to the Stockholders Agreement
and currently hold the majority of the Registrable Securities currently outstanding (each, a “Stockholder”,
and collectively, the “Stockholders”) and Neurotrope, Inc., a Nevada corporation (the “Company”)
(the Company and the Stockholders, collectively, the “Parties”). Capitalized terms used but not defined herein
shall have the meanings ascribed thereto in that certain Preferred Stockholders Agreement, dated as of August 23, 2013 (as amended,
the “Stockholders Agreement”).

 

RECITALS

 

WHEREAS, the
Parties are each a party to the Stockholders Agreement; and

 

WHEREAS, pursuant
to Section 8.7 of the Stockholders Agreement, Section 2 of the Stockholders Agreement may be amended and the observance of any
term of Section 2 may be waived (either generally or in a particular instance, and either retroactively or prospectively) with
the written consent of the Company and the holders of a majority of the Registrable Securities then outstanding; and

 

WHEREAS, and
the Stockholders who have executed this Amendment currently hold the majority of the Registrable Securities currently outstanding;
and

 

WHEREAS, the
Parties desire to amend the Stockholders Agreement in order to amend and waive certain registration rights contained therein as
such rights pertain to the registration obligations set forth in the Securities Purchase Agreement, dated November ___, 2015 (the
“SPA”), by and among the Company and the Buyers (as such term is defined in the SPA), and the various agreements
relating to the SPA, including the registration obligations pursuant to the Registration Rights Agreement, dated as of the same
date as the SPA, by and among the Company and the Buyers (the “RRA”).

 

NOW, THEREFORE,
in consideration of the promises and mutual covenants contained herein, and the execution of the other agreements referenced above,
the Parties hereby agree as follows:

 

1.          Representations
of the Company.

 

(a)          The
Company hereby represents and warrants to the Stockholders that on December 1, 2014 it filed a registration statement on Form S-1
(SEC file number 333-200664) with the SEC, which was amended by the Company (by pre-effective amendments) and declared effective
by the SEC on February 12, 2015 at 5:00 P.M. On April 8, 2015, the Company filed Post-Effective Amendment No. 1 to Form S-1 (on
Form S-1/A) with the SEC with respect to the same registration statement, which was declared effective on May 11, 2015 (such registration
statement as amended and supplemented from time-to-time, the “S-1 Registration Statement”). As of the date of
this Amendment, the SEC has not issued a stop-order with respect to the S-1 Registration Statement.

 

     

     

    

 

(b)          With
a view to making available to the Stockholders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may
at any time permit a Stockholder to sell securities of the Company to the public without registration or pursuant to an applicable
registration statement, the Company shall make and keep available adequate current public information, as those terms are understood
and defined in SEC Rule 144.

 

2.          Indemnification.

 

(a)          To
the extent permitted by law, the Company will indemnify and hold harmless each selling Stockholder, and the partners, members,
officers, directors, and stockholders of each such Stockholder; legal counsel and accountants for each such Stockholder; any underwriter
(as defined in the Securities Act) for each such Stockholder; and each Person, if any, who controls such Stockholder or underwriter
within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Stockholder,
underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection
with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided,
however, that the indemnity agreement contained in this Section 2 shall not apply to amounts paid in settlement of any such
claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably
withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions
made in reliance upon and in conformity with written information furnished by or on behalf of any such Stockholder, underwriter,
controlling Person, or other aforementioned Person expressly for use in connection with such registration.

 

(b)          To
the extent permitted by law, each selling Stockholder, severally and not jointly, will indemnify and hold harmless the Company,
and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the
Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in
the Securities Act), any other Stockholder selling securities in such registration statement, and any controlling Person of any
such underwriter or other Stockholder, against any Damages, in each case only to the extent that such Damages arise out of or are
based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such
selling Stockholder expressly for use in connection with such registration; and each such selling Stockholder will pay to the Company
and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or
defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however,
that the indemnity agreement contained in this Section 2 shall not apply to amounts paid in settlement of any such claim or proceeding
if such settlement is effected without the consent of the Stockholder, which consent shall not be unreasonably withheld; and provided
further that in no event shall the aggregate amounts payable by any Stockholder by way of indemnity or contribution under
Sections 2 exceed the proceeds from the offering received by such Stockholder (net of any Selling Expenses paid by such Stockholder),
except in the case of fraud or willful misconduct by such Stockholder.

 

    	 	-2-	 

     

    

 

(c)          Promptly
after receipt by an indemnified party under this Section 2 of notice of the commencement of any action (including any
governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in
respect thereof is to be made against any indemnifying party under this Section 2, give the indemnifying party notice of the commencement
thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so
desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof
with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all
other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate
counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel
retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified
party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within
a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified
party under this Section ‎2, to the extent that such failure materially prejudices the indemnifying party’s ability to
defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have
to any indemnified party otherwise than under this Section ‎2.

 

(d)          To
provide for just and equitable contribution to joint liability under the Securities Act in any case in which either (i) any party
otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section ‎2 but it is judicially
determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal
or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact
that this Section ‎2 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required
on the part of any party hereto for which indemnification is provided under this Section ‎2, then, and in each such case, such
parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after
contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party
and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage,
liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying
party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue
statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying
party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to
correct or prevent such statement or omission; provided, however, that, in any such case, (x) no Stockholder will
be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold
by such Stockholder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent
misrepresentation; and provided further that in no event shall a Stockholder’s liability pursuant to this Section
‎2 exceed the proceeds from the offering received by such Stockholder (net of any Selling Expenses paid by such Stockholder),
except in the case of willful misconduct or fraud by such Stockholder.

 

    	 	-3-	 

     

    

 

(e)          Notwithstanding
the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered
into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control.

 

(f)          Unless
otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Stockholders under this Section ‎2 shall survive the completion of any offering of Registrable Securities
in a registration under this Section ‎2, and otherwise shall survive the termination of this Agreement.

 

3.          Amendment
of Section 2.2 (Company Registration). Pursuant to Section 8.7 of the Stockholders Agreement, Section 2.2 of the Stockholders
Agreement is hereby amended to include the following as a new sentence following the last sentence of Section 2.2:

 

“Notwithstanding the foregoing,
this Section 2.2 shall not apply and shall have no force or effect with respect to the registration statement(s) contemplated by
the SPA, the RRA and related agreements.”

 

4.          Amendment
of Section 2.10 (Limitations on Subsequent Registration Rights). Pursuant to Section 8.7 of the Stockholders Agreement, Section
2.10 of the Stockholders Agreement is hereby amended to include the following as a new sentence following the last sentence of
Section 2.10:

 

“Notwithstanding the foregoing,
this Section 2.10 shall not apply and shall have no force or effect with respect to the registration statement(s) contemplated
by the SPA, the RRA and related agreements.”

 

5.          Amendment
of Section 2.12 (Restrictions on Transfer). Pursuant to Section 8.7 of the Stockholders Agreement, Section 2.12 of the Stockholders
Agreement is hereby amended and restated (both retroactively and prospectively) to read in its entirety as follows:

 

“2.12         Restrictions
on Transfer.

 

“(a)          The
Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer,
that is not made in compliance with the provisions of the Securities Act.

 

    	 	-4-	 

     

    

 

“(b)          Each
certificate or instrument representing (i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities
issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization,
merger, consolidation, or similar event, shall (unless resold pursuant to a Public Offering (as hereafter defined) or SEC Rule
144 or as otherwise permitted by the provisions of Subsection 2.12‎(c) hereof or as otherwise permitted by applicable
securities laws) be stamped or otherwise imprinted with a legend substantially in the following form:

 

“THE SECURITIES REPRESENTED
HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE
SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY
REQUIREMENTS OF SAID ACT.

 

“The Holders
consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities
in order to implement the restrictions on transfer set forth in this Subsection 2.12. The provisions of Section 2, including
without limitation the transfer restrictions pursuant to this Subsection 2.12 shall terminate and be of no further force
and effect with respect to any (former) Restricted Securities following the sale or other transfer of such Restricted Securities
pursuant to a Public Offering or SEC Rule 144 or as otherwise permitted by the provisions of Subsection 2.12‎(c) hereof
or as otherwise permitted by applicable securities law.

 

“(c)          The
holder of each certificate representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the
provisions of this Section ‎2. If reasonably requested by the Company, any proposed transfer that is not made pursuant
to an effective registration statement under the Securities Act shall be accompanied at such Holder’s expense by either (i)
a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed
to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii)
a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities
without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or
(iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer
of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted
Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice
given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter in any
transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided
that each transferee agrees in writing to be subject to the terms of this Subsection ‎2.12. A stock certificate shall
not bear a restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order
to establish compliance with any provisions of the Securities Act. The obligations set forth in this Subsection 2.12 are
in addition to any other restrictions on transfer set forth in this Agreement.”

 

6.          Waiver
of Section 6 (Lock-Up). The Company hereby waives any rights pursuant to Section 6 of the Stockholders Agreement.

 

    	 	-5-	 

     

    

 

7.          Conversion
to Form S-3. Pursuant to Section 8.7 of the Stockholders Agreement, the Stockholders Agreement is hereby amended to include
the following as a new Section 2.15:

 

“2.15         Conversion
to Form S-3. Promptly following the filing of the Registration Statement (as such term is defined in the RRA) as contemplated
in Section 2(a) of the RRA, if the Company is then eligible to do so, it shall prepare and file a post-effective amendment to the
S-1 Registration Statement on Form S-3 with the United States Securities and Exchange Commission, to convert the S-1 Registration
Statement into a registration statement on Form S-3.”

 

8.          Defined
Terms. The parties hereby agree that the Stockholders Agreement is further amended to incorporate by reference the additional
terms defined herein, including without limitation the definitions of SPA, RRA and S-1 Registration Statement.

 

9.          Waiver.
The Company and the Stockholders hereby waive, retroactively and prospectively, any of the rights of the Stockholders of Registrable
Securities under Section 2 of the Stockholders Agreement, to the extent such right conflicts or previously conflicted with the
Stockholders Agreement as amended by this Amendment.

 

10.         Effect
of this Amendment. This Amendment shall become effective upon execution by the Company and the Stockholders. There are no further
changes to the terms of the Stockholders Agreement. Except as would be inconsistent with the terms of this Amendment, all other
terms and conditions of the Stockholders Agreement shall remain in full force and effect and be unaffected by this Amendment. The
Stockholders Agreement, as amended hereby, embodies the entire agreement and understanding between the Parties with respect to
the subject matter thereof and hereof and supersedes all prior discussions, understandings and agreements concerning such subject
matter.

 

11.         Facsimile
and Counterparts. This Amendment may be executed in one or more counterparts by the Parties by signature of a person having
authority to bind the Party, each of which when executed and delivered by facsimile, electronic transmission or by mail delivery,
will be an original and all of which shall constitute but one and the same Agreement.

 

**********

 

    	 	-6-	 

     

    

 

IN WITNESS WHEREOF,
the Parties hereto have caused this Amendment No. 2 to Preferred Stockholders Agreement to be executed as of the Amendment Effective
Date.

 

	 	NEUROTROPE, INC.
	 	 	 
	 	By:	 /s/ Robert Weinstein 

 

	 	Name:	Robert Weinstein
	 	Title:	Chief Financial Officer, Executive Vice President, Secretary and Treasurer

 

[Amendment No. 2 Signature Page – Neurotrope, Inc.]

 

     

     

    

 

IN WITNESS WHEREOF,
the Parties hereto have caused this Amendment No. 2 to Preferred Stockholders Agreement to be executed as of the Amendment Effective
Date.

 

STOCKHOLDER:

 

(Please complete and execute below using the signature block
applicable to the stockholder. Please make sure that the signature block below reflects the same party that signed the Stockholders
Agreement)

 

Individual Stockholder sign below:

 

	 	 
	(Print name of individual)	 
	 	 
	 	 
	(Signature of individual)	 

 

Corporations, partnerships, trusts and other entities
sign below:

 

	NTR21 Holdings, LLC	 
	(Print full legal name of entity)	 
	 	 	 
	By:	NTR21 Equities Corp.	 
	(Signature of authorized signatory)	 

 

	Name:	/s/ Charles S. Ramat	 
	 	Charles S. Ramat	 

 

	Title:	Managing Partner	 

 

[Amendment No. 2 Signature Page –
Stockholders]

 

     

     

    

 

IN WITNESS WHEREOF, the Parties hereto
have caused this Amendment No. 2 to Preferred Stockholders Agreement to be executed as of the Amendment Effective Date.

 

STOCKHOLDER:

 

(Please complete and execute below using the signature block
applicable to the stockholder. Please make sure that the signature block below reflects the same party that signed the Stockholders
Agreement)

 

Individual Stockholder sign below:

 

	 	 
	(Print name of individual)	 
	 	 
	 	 
	(Signature of individual)	 

 

Corporations, partnerships, trusts and other entities
sign below:

 

	Northlea Partners, LLLP	 
	(Print full legal name of entity)	 
	 	 	 
	By:	/s/John H. Abeles, MD	 
	(Signature of authorized signatory)	 

 

	Name:	 John H. Abeles, MD	 

 

	Title:	Managing Member	 

 

[Amendment No. 2 Signature Page –
Stockholders]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]